Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation

---

Copy For Citation

Capo V., Castiello M. C., Fontana E., Penna S., Bosticardo M., Draghici E., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol.142, no.3, pp.928-949, 2018 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 142 Issue: 3
• Publication Date: 2018
• Doi Number: 10.1016/j.jaci.2017.11.015
• Journal Name: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.928-949
• Hacettepe University Affiliated: No

Abstract

Background: Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity and caused by defects in lymphoid-specific V(D)J recombination. Most patients carry hypomorphic mutations in recombination-activating gene (RAG) 1 or 2. Hematopoietic stem cell transplantation is the standard treatment; however, gene therapy (GT) might represent a valid alternative, especially for patients lacking a matched donor.